Shopping Cart
- Remove All
Your shopping cart is currently empty
NW-1689 is a process-related impurity of safinamide mesilate (SAFM), which is a medication used in the treatment of Parkinson's disease (PD). SAFM acts as a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium and N-type calcium channels. These actions assist in reducing dopamine breakdown and suppressing glutamate release. NW-1689 shares structural similarities with SAFM and exhibits comparable pharmacological effects, making it applicable in Parkinson's disease research.


| Description | NW-1689 is a process-related impurity of safinamide mesilate (SAFM), which is a medication used in the treatment of Parkinson's disease (PD). SAFM acts as a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium and N-type calcium channels. These actions assist in reducing dopamine breakdown and suppressing glutamate release. NW-1689 shares structural similarities with SAFM and exhibits comparable pharmacological effects, making it applicable in Parkinson's disease research. |
| Molecular Weight | 246.23 |
| Formula | C14H11FO3 |
| Cas No. | 405-85-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.